Five Prime Therapeutics Announces Pricing of Initial Public Offering

September 17, 2013

Five Prime (NASDAQ: FPRX), a clinical-stage company, discovers and develops novel protein therapeutics for cancer and inflammatory diseases, and finds new targets through a proprietary screening platform of >5,600 human extracellular proteins.
More »

Ariosa Diagnostics and Fleury Group Announce Offering of the Highly Accurate Harmony(TM) Prenatal Test in Brazil to Assess Risk for Chromosome Conditions in Singleton and Twin Pregnancies

September 12, 2013

With over 3,000 clinical laboratories and hospitals throughout Brazil, the Fleury Group selected Harmony as its non-invasive prenatal test of choice for obstetric healthcare providers to perform risk analysis of conditions such as Down syndrome.
More »

Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries

September 4, 2013

Syndax and Eddingpharm entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat, an epigenetic therapy for cancer, in China and other Asian countries/regions.
More »